Vermillion Reports Landmark OVA1 Cost-Effectiveness Analysis Compared to Current Standard at ACMQC
March 27, 2015 at 08:02 AM EDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced initial results ...